DNA gyrase

DNA gyrase
Identifiers
EC no.5.6.2.2
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Search
PMCarticles
PubMedarticles
NCBIproteins

DNA gyrase, or simply gyrase, is an enzyme within the class of topoisomerase and is a subclass of Type II topoisomerases[1] that reduces topological strain in an ATP dependent manner while double-stranded DNA is being unwound by elongating RNA-polymerase[2] or by helicase in front of the progressing replication fork.[3][4] It is the only known enzyme to actively contribute negative supercoiling to DNA, while it also is capable of relaxing positive supercoils. It does so by looping the template to form a crossing, then cutting one of the double helices and passing the other through it before releasing the break, changing the linking number by two in each enzymatic step. This process occurs in bacteria, whose single circular DNA is cut by DNA gyrase and the two ends are then twisted around each other to form supercoils. Gyrase is also found in eukaryotic plastids: it has been found in the apicoplast of the malarial parasite Plasmodium falciparum[5][6] and in chloroplasts of several plants.[7] Bacterial DNA gyrase is the target of many antibiotics, including nalidixic acid, novobiocin, albicidin, and ciprofloxacin.

The unique ability of gyrase to introduce negative supercoils into DNA at the expense of ATP hydrolysis[1] is what allows bacterial DNA to have free negative supercoils. The ability of gyrase to relax positive supercoils comes into play during DNA replication and prokaryotic transcription. The helical nature of the DNA causes positive supercoils to accumulate ahead of a translocating enzyme, in the case of DNA replication, a DNA polymerase. The ability of gyrase (and topoisomerase IV) to relax positive supercoils allows superhelical tension ahead of the polymerase to be released so that replication can continue.

  1. ^ a b Garrett RH, Grisham CM (2013). Biochemistry (5th, International ed.). United States: Mary Finch. p. 949. ISBN 978-1-133-10879-5.
  2. ^ Sutormin D, Rubanova N, Logacheva M, Ghilarov D, Severinov K (2018). "Single-nucleotide-resolution mapping of DNA gyrase cleavage sites across the Escherichia coli genome". Nucleic Acids Research. 47 (3): 1373–1388. doi:10.1093/nar/gky1222. PMC 6379681. PMID 30517674.
  3. ^ Wigley DB, Davies GJ, Dodson EJ, Maxwell A, Dodson G (June 1991). "Crystal structure of an N-terminal fragment of the DNA gyrase B protein". Nature. 351 (6328): 624–9. Bibcode:1991Natur.351..624W. doi:10.1038/351624a0. PMID 1646964. S2CID 4373125.
  4. ^ Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC (August 1997). "Crystal structure of the breakage-reunion domain of DNA gyrase". Nature. 388 (6645): 903–6. Bibcode:1997Natur.388..903M. doi:10.1038/42294. PMID 9278055. S2CID 4320715.
  5. ^ Dar MA, Sharma A, Mondal N, Dhar SK (March 2007). "Molecular cloning of apicoplast-targeted Plasmodium falciparum DNA gyrase genes: unique intrinsic ATPase activity and ATP-independent dimerization of PfGyrB subunit". Eukaryotic Cell. 6 (3): 398–412. doi:10.1128/ec.00357-06. PMC 1828931. PMID 17220464.
  6. ^ Dar A, Prusty D, Mondal N, Dhar SK (November 2009). "A unique 45-amino-acid region in the toprim domain of Plasmodium falciparum gyrase B is essential for its activity". Eukaryotic Cell. 8 (11): 1759–69. doi:10.1128/ec.00149-09. PMC 2772398. PMID 19700639.
  7. ^ Evans-Roberts K, Mitchenall L, Wall M, Leroux J, Mylne J, Maxwell A (2016). "DNA Gyrase Is the Target for the Quinolone Drug Ciprofloxacin in Arabidopsis thaliana". Journal of Biological Chemistry. 291 (7): 3136–44. doi:10.1074/jbc.M115.689554. PMC 4751362. PMID 26663076.